Among patients with HFpEF across 11 Asian regions, 12.1% died or were hospitalized for heart failure within 1 year, with Southeast Asians at higher risk for adverse outcomes.
Cohort (n=1,204)
Yes
HFpEF in Asia affects relatively young patients with a high burden of comorbidities, with significant regional differences in comorbidities, cardiac remodeling, and outcomes.
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem. Unfortunately, little is known about HFpEF across Asia. METHODS AND RESULTS: We prospectively studied clinical characteristics, echocardiographic parameters and outcomes in 1204 patients with HFpEF (left ventricular ejection fraction ≥50%) from 11 Asian regions, grouped as Northeast Asia (Hong Kong, Taiwan, China, Japan, Korea, n = 543), South Asia (India, n = 252), and Southeast Asia (Malaysia, Thailand, Singapore, Indonesia, Philippines, n = 409). Mean age was 68 ±12 years (37% were < 65 years) and 50% were women. Seventy per cent of patients had ≥2 co-morbidities, most commonly hypertension (71%), followed by anaemia (57%), chronic kidney disease (50%), diabetes (45%), coronary artery disease (29%), atrial fibrillation (29%) and obesity (26%). Southeast Asian patients had the highest prevalence of all co-morbidities except atrial fibrillation, South Asians had the lowest prevalence of all co-morbidities except anaemia and obesity, and Northeast Asians had more atrial fibrillation. Left ventricular hypertrophy and concentric remodelling were most prominent among Southeast and South Asians, respectively (P < 0.001). Overall, 12.1% of patients died or were hospitalized for heart failure within 1 year. Southeast Asians were at higher risk for adverse outcomes, independent of co-morbidity burden and cardiac geometry. CONCLUSION: These first prospective multinational data from Asia show that HFpEF affects relatively young patients with a high burden of co-morbidities. Regional differences in types of co-morbidities, cardiac remodelling and outcomes of HFpEF across Asia have important implications for public health measures and global HFpEF trial design.
Tromp et al. (2018) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=1,204). Geographic region (Northeast, South, and Southeast Asia) vs. Between regions was evaluated on Death or hospitalization for heart failure within 1 year. Among patients with HFpEF across 11 Asian regions, 12.1% died or were hospitalized for heart failure within 1 year, with Southeast Asians at higher risk for adverse outcomes.